A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00332748
Recruitment Status : Terminated
First Posted : June 2, 2006
Last Update Posted : March 2, 2010
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine what effects Esomeprazole (Nexium) has on increasing or decreasing the amount of oral taxane in the blood, and to determine the safety of oral taxane and effect of oral taxane on the cancer.

Condition or disease Intervention/treatment Phase
Cancer Drug: Oral Taxane Phase 1

Study Type : Interventional  (Clinical Trial)
Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients With Advanced Malignancies
Study Start Date : December 2006
Actual Primary Completion Date : December 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. To assess the safety of taking Nexium in combination with oral taxane and the effect this combination has on oral taxane's exposure levels in the body.

Secondary Outcome Measures :
  1. To assess the safety of a single dose of oral taxane followed by a therapeutic regimen of oral taxane administered twice weekly

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Advanced cancers excluding cancers within the blood
  • Adequate kidney and liver function
  • > = 4 weeks from last course of chemotherapy

Exclusion Criteria:

  • Inability to swallow capsules
  • Other active medical disorder
  • Abnormal heart function or use of drugs that affect the heart

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00332748

United States, Delaware
Local Institution
Newark, Delaware, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
Local Institution
Amsterdam, Netherlands
Sponsors and Collaborators
Bristol-Myers Squibb

Additional Information: Identifier: NCT00332748     History of Changes
Other Study ID Numbers: CA165-030
First Posted: June 2, 2006    Key Record Dates
Last Update Posted: March 2, 2010
Last Verified: September 2007

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents